



indoco remedies limited

INDOCO HOUSE, 166 C. S. T. ROAD, SANTACRUZ (EAST), MUMBAI - 400 098 (INDIA) ● Website : www.indoco.com
PHONES : (91-22) 3386 1000 / 3386 1250 ● FAX : (91-22) 2652 3067 / 2652 3976 ● CIN : L85190MH1947PLC005913

November 07, 2017

To
The Listing Department
National Stock Exchange of India Ltd
Exchange Plaza
Bandra Kurla Complex
Bandra (East)
Mumbai 400 051

To
The Listing Department
Bombay Stock Exchange Limited
Floor 25, P. J. Towers,
Dalal Street,
Mumbai - 400 001

Dear Sirs,

Sub: Unaudited Financial Results for the quarter ended 30th September, 2017


It is hereby informed that, the Board of Directors at their meeting have approved and taken on record the unaudited financial results of the Company for the quarter ended 30th September, 2017.

Enclosed a copy of the said unaudited results as per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 alongwith the Limited Review Certificate issued by our Statutory Auditors M/s. Gokhale & Sathe, Chartered Accountants.

The meeting commenced at 11.00 am and concluded at 12 Noon

Thanking you,

Yours faithfully,
For Indoco Remedies Limited


Jayshankar Menon
Company Secretary

INDOCO REMEDIES LIMITED

Regd. Office : Indoco House, 166, CST Road, Kalina, Santacruz (E), Mumbai 400 098

Tel: +91-22-26541851/55 Fax: +91-22-26520787 Email: compliance.officer@indoco.com

Web: www.indoco.com CIN: L85190MH1947PLC005913

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2017

(₹ In Lakhs)

Sr. No	Particulars	Quarter ended 30.09.2017 (Unaudited)	Quarter ended 30.06.2017 (Unaudited)	Quarter ended 30.09.2016 (Unaudited)	Half year ended 30.09.2017 (Unaudited)	Half year ended 30.09.2016 (Unaudited)	Year ended 31.03.2017 (Audited)
1	Income from Operations						
	(a) Revenue from Operations	28,004	20,422	27,639	48,426	52,889	1,06,665
	(b) Other Operating Income	477	479	526	956	1,041	2,741
	Total Income from Operations (Net) (a+b)	28,481	20,901	28,165	49,382	53,930	1,09,406
2	Other Income	234	86	102	320	133	414
3	Total Income (1+2)	28,715	20,987	28,267	49,702	54,063	1,09,820
4	Expenses						
	(a) Cost of materials consumed	7,551	6,057	7,859	13,608	14,963	30,278
	(b) Purchases of stock-in-trade	1,499	1,785	2,908	3,284	4,689	8,039
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	975	(731)	(1,060)	244	(1,039)	(156)
	(d) Employee Benefits Expense	5,537	5,630	5,341	11,167	10,415	21,605
	(e) Research & Development Expense	1,175	1,357	1,204	2,532	2,403	5,171
	(f) Other Expenses	7,651	6,674	7,654	14,325	14,010	28,807
	(g) Finance Costs	697	609	221	1,306	515	616
	(h) Depreciation and Amortisation Expense	1,721	1,687	1,668	3,408	3,348	6,327
	Total Expenses	26,806	23,068	25,795	49,874	49,304	1,00,687
5	Profit/(Loss) before Tax (3-4)	1,909	(2,081)	2,472	(172)	4,759	9,133
6	Tax Expenses	(67)	92	259	25	567	1,388
7	Profit/(Loss) for the period (5-6)	1,976	(2,173)	2,213	(197)	4,192	7,745
8	Other Comprehensive Income						
a	i) Items that will not be reclassified to profit and loss	(5)	(5)	(5)	(10)	(11)	20
	ii) Income tax on relating to this item	2	2	5	3	4	(7)
b	i) Items that may be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income	(3)	(3)	-	(7)	(7)	13
	Total Comprehensive Income for the year	1,973	(2,176)	2,213	(204)	4,185	7,768
9	Paid up Equity Share Capital (Face value ₹ 2/- each)	1,843	1,843	1,843	1,843	1,843	1,843
10	Other Equity	-	-	-	-	-	63,345
11	Earnings per share (of ₹ 2/- each)						
	(a) Basic- in ₹	2.14	(2.36)	2.40	(0.21)	4.55	8.40
	(b) Diluted- in ₹	2.14	(2.36)	2.40	(0.21)	4.55	8.40

Notes :

1 Above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 07th November, 2017.

2 The company has only one primary reportable segment of activity, namely, Pharmaceuticals.

Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:

(₹ In Lakhs)

Net Sales and Income from Operations	Quarter ended 30.09.2017 (Unaudited)	Quarter ended 30.06.2017 (Unaudited)	Quarter ended 30.09.2016 (Unaudited)	Half year ended 30.09.2017 (Unaudited)	Half year ended 30.09.2016 (Unaudited)	Year ended 31.03.2017 (Audited)
India	19,749	11,022	17,674	30,771	32,905	61,597
Outside India	8,255	9,400	9,965	17,655	19,984	45,068
Total	28,004	20,422	27,639	48,426	52,889	1,06,665

3 The Board has approved the closure of the Company's non operational Subsidiary and Associate LLP viz Indoco Pharmchem Limited and Indoco Analytical Solution -LLP respectively. The closure will have no significant or material impact on the Company's Financials.

4 The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 30th September, 2017.


5 The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.

6 STATEMENT OF ASSETS AND LIABILITIES

(₹ In Lakhs)

Sr. No	Particulars	As at 30.09.2017 (Unaudited)	As at 31.03.2017 (Audited)
A	ASSETS		
1	Non-Current Assets		
	(a) Property, Plant and Equipment	37,982	39,276
	(b) Capital Work in Progress	10,395	4,033
	(c) Other Intangible Assets	4,283	4,700
	(d) Intangible Assets under Development	5,743	5,030
	(e) Financial Assets		
	(i) Investments	285	282
	(ii) Loans	94	137
	(iii) Others	1,758	1,669
	(f) Deferred Tax Assets (Net)	2,742	2,763
	(g) Current Tax Assets (Net)	1,047	425
	(h) Other Non-Current Assets	2,879	4,348
	Total - Non-Current Assets	67,208	62,663
2	Current Assets		
	(a) Inventories	19,017	18,504
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade Receivables	21,432	21,573
	(iii) Cash and Cash Equivalents	2,681	5,992
	(iv) Other Bank Balance	338	248
	(v) Loans	155	152
	(vi) Others	307	1,291
	(c) Other Current Assets	12,255	9,294
	(d) Assets Classified as held for Sale	-	7
	Total - Current Assets	56,185	57,061
	Total - Assets	1,23,393	1,19,724
B	Liabilities and Equity		
1	Equity		
	(a) Equity Share Capital	1,843	1,843
	(b) Other Equity	61,366	63,345
	Total Equity	63,209	65,188
2	Liabilities		
a)	Non-Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	12,487	13,231
	(ii) Other Financial Liabilities	718	698
	(b) Provisions	2,000	1,783
	(c) Other Non-Current Liabilities	267	445
	Total - Non-Current Liabilities	15,472	16,157
b)	Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	13,666	11,836
	(ii) Trade Payables	14,539	16,417
	(iii) Other Financial Liabilities	11,225	6,843
	(b) Provisions	2,563	2,918
	(c) Other Current Liabilities	2,719	365
	Total - Current Liabilities	44,712	38,379
	Total, Liabilities	60,184	54,536
	Total - Equity and Liabilities	1,23,393	1,19,724

By Order of the Board
For Indoco Remedies Ltd


Suresh G. Kare
Chairman


Place : Mumbai
Date : 7th November, 2017



Limited Review Report on quarterly and year to date unaudited Standalone Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of
Indoco Remedies Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of Indoco Remedies Limited ("the Company") for the quarter and half year ended 30th September 2017 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 7th November 2017. Our responsibility is to issue a report on the statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of Company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. The comparative unaudited standalone financial results of the Company for the quarter and six months ended 30th September 2016 and for the year ended 31st March 2017 included in this Statement had been reviewed/audited by Patkar & Pendse, Chartered Accountants whose report dated 26th October 2016 and 26th May 2017 respectively expressed unmodified opinion on those unaudited standalone financial results for the six months ended 30th September 2016 and audited financial results for the year ended 31st March 2017. Additionally, the report of Patkar & Pendse, Chartered Accountants dated 9th August 2017 on the financial results for the quarter ended 30th June 2017 which have been included in this Statement, expressed an unmodified opinion and which has been furnished to us by the Management, has been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.






Limited Review Report on Unaudited Standalone Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Circular dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Gokhale & Sathe
Chartered Accountants
Firm's Registration No: 103264W



Rahul Joglekar
Partner

Membership No:129389



Place: Mumbai

Date : 7th November 2017